Table 4: Patients' responses compared to PD-L1 expression.
|
NSCLC type |
Age/Gender |
PD-L1 expression |
Treatment given |
Response |
|
Adenocarcinoma |
63 F |
G2 |
Nevolumab |
Progression |
|
Adenocarcinoma |
84 M |
G5 |
Nevolumab |
Partial response |
|
Adenocarcinoma |
77 M |
G2 |
Nevolumab |
Progression |
|
Adenocarcinoma |
64 F |
G2 |
Pembrolizumab |
Progression |
|
Adenocarcinoma |
75 M |
G4-5 |
Nevolumab |
Progression |
|
Adenocarcinoma |
86 F |
G4-5 |
Nevolumab |
Partial response |
|
Adenocarcinoma |
49 F |
G2 |
Pembrolizumab |
Progression |
|
Adenocarcinoma |
61 M |
G5 |
Pembrolizumab |
Progression |
|
Adenocarcinoma |
64 M |
G3 |
Pembrolizumab |
Progression |
|
SCC |
85 F |
G4 |
Pembrolizumab |
Progression |
|
Adenocarcinoma |
61 M |
G5 |
Pembrolizumab |
Complete response |